About Cholera Vaccines
The cholera vaccines market appears to be concentrated due to the presence of few established players. The major vendors in the market compete based on pricing and presence across the world. The presence of a rich pipeline, strategic partnerships, and operational base are the other major competitive factors among cholera vaccine manufacturers. Cholera vaccines can be segmented into three product types which includes Shanchol, DUKORAL, and Vaxchora. Shanchol segment accounted for the major share of the cholera vaccines market. Cholera is very common in countries such as Congo, Yemen, South Sudan, Mozambique, and Haiti and these countries are the major adopters of Shanchol since this vaccine provides better long-term protection for children especially under the age of six.
Technavio’s analysts forecast the global cholera vaccines market to grow at a CAGR of 9.56% during the period 2018-2022.
Covered in this report
The report covers the present scenario and the growth prospects of the global cholera vaccines market for 2018-2022. To calculate the market size, the report considers the revenue generated from the sales of cholera vaccines.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Cholera Vaccines Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• PaxVax
• Sanofi
• Valneva
Market driver
• Lack of proper sanitation and consumption of contaminated food
• For a full, detailed list, view our report
Market trend
• Increasing number of public-private initiatives
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2022 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
• Market outline
PART 05: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 06: MARKET SIZING
• Market definition
• Market sizing 2017
• Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 08: PIPELINE LANDSCAPE
PART 09: MARKET SEGMENTATION BY PRODUCT
• Overview
• Comparison by product
• Shanchol
• DUKORAL
• Vaxchora
• Market opportunity by product
PART 10: SEGMENTATION BY GEOGRAPHY
• Overview
• Regional comparison
• Americas
• EMEA
• APAC
• Key leading countries
• Market opportunity
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
• Market challenges
PART 13: MARKET TRENDS
• Increasing number of public-private initiatives
• Focus on developing countries
PART 14: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive landscape
PART 15: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• PaxVax
• Sanofi
• Valneva
PART 16: APPENDIX
• List of abbreviations
List of Exhibits
Exhibit 01: Cholera: Overview
Exhibit 02: Severe form of cholera
Exhibit 03: Major cholera outbreaks 2010-2017
Exhibit 04: Parent market
Exhibit 05: Market characteristics
Exhibit 06: Global cholera vaccines market: Segmentation
Exhibit 07: Market definition: Inclusions and exclusions checklist
Exhibit 08: Market size 2017
Exhibit 09: Validation techniques employed for market sizing 2017
Exhibit 10: Global cholera vaccines market 2017-2022 ($ millions)
Exhibit 11: Global cholera vaccines market: Year-over-year growth 2018-2022 (%)
Exhibit 12: Five forces analysis 2017
Exhibit 13: Five forces analysis 2022
Exhibit 14: Bargaining power of buyers
Exhibit 15: Bargaining power of suppliers
Exhibit 16: Threat of new entrants
Exhibit 17: Threat of substitutes
Exhibit 18: Threat of rivalry
Exhibit 19: Market condition 2017
Exhibit 20: Pipeline landscape by sponsors or collaborators
Exhibit 21: Key clinical trials
Exhibit 22: Global cholera vaccines market: Segmentation by product 2017-2022 (% share)
Exhibit 23: Comparison by product
Exhibit 24: Description of Shanchol
Exhibit 25: Global Shanchol market 2017-2022 ($ millions)
Exhibit 26: Global Shanchol market: Year-over-year growth 2018-2022 (%)
Exhibit 27: Description of DUKORAL
Exhibit 28: Global DUKORAL market 2017-2022 ($ millions)
Exhibit 29: Global DUKORAL market: Year-over-year growth 2018-2022 (%)
Exhibit 30: Global Vaxchora market 2017-2022 ($ millions)
Exhibit 31: Global Vaxchora market: Year-over-year growth 2018-2022 (%)
Exhibit 32: Market opportunity by product
Exhibit 33: Global cholera vaccines market: Segmentation by geography 2017-2022 (% share)
Exhibit 34: Regional comparison
Exhibit 35: Cholera vaccines market in Americas 2017-2022 ($ millions)
Exhibit 36: Cholera vaccines market in Americas: Year-over-year growth 2018-2022 (%)
Exhibit 37: Cholera vaccines market 2017-2022 ($ millions)
Exhibit 38: Cholera vaccines market in EMEA: Year-over-year growth 2018-2022 (%)
Exhibit 39: Cholera vaccines market in APAC 2017-2022 ($ millions)
Exhibit 40: Cholera vaccines market in APAC: Year-over-year growth 2018-2022 (%)
Exhibit 41: Key leading countries: Prevalence of cholera
Exhibit 42: Market opportunity
Exhibit 43: Countries with high proportion of population without sanitation 2014
Exhibit 44: Number of departures from US to Asia 2012-2015
Exhibit 45: Departures to top Asian countries from US 2015
Exhibit 46: Initiatives to prevent and manage cholera
Exhibit 47: Vendor landscape
Exhibit 48: Landscape disruption
Exhibit 49: Competitive structure analysis
Exhibit 50: Vendors covered
Exhibit 51: Vendor classification
Exhibit 52: Market positioning of vendors
Exhibit 53: PaxVax: Overview
Exhibit 54: PaxVax: Business segments
Exhibit 55: PaxVax: Organizational developments
Exhibit 56: PaxVax: Geographic focus
Exhibit 57: PaxVax: Segment focus
Exhibit 58: PaxVax: Key offerings
Exhibit 59: PaxVax: Key customers
Exhibit 60: Sanofi: Overview
Exhibit 61: Sanofi: Business segments
Exhibit 62: Sanofi: Organizational developments
Exhibit 63: Sanofi: Geographic focus
Exhibit 64: Sanofi: Segment focus
Exhibit 65: Sanofi: Key offerings
Exhibit 66: Sanofi: Key customers
Exhibit 67: Valneva: Overview
Exhibit 68: Valneva: Business segments
Exhibit 69: Valneva: Organizational developments
Exhibit 70: Valneva: Geographic focus
Exhibit 71: Valneva: Segment focus
Exhibit 72: Valneva: Key offerings
Exhibit 73: Valneva: Key customers
